annotations:
  0:
    - measure: Composite
    - object: CHD Death
    - object: Non-fatal MI
    - object: Ischemic Stroke
  1:
    - measure: Number
    - object: Acute Febrile Illness
  2:
    - measure: Percentage of Participants
    - object: Alanine Aminotransferase (ALT) Level Elevation More Than 1.5 Times Upper Limit of Normal
    - object: Aspartate Aminotransferase (AST) Level Elevation More Than 1.5 Times Upper Limit of Normal
  3:
    - measure: Change from Baseline
    - object: CD4/CD8 Cell Counts
  4:
    - measure: Number of Subjects
    - object: Toxicity
  5:
    - measure: Costs
    - object: Referrals to Radiography
  6:
    - measure: Duration
    - object: Solicited Local Symptoms
  7:
    - measure: Percentage of Responder Subjects
    - object: Partial Onset Seizures (Type I)
  8:
    - measure: Change from Baseline
    - object: Leibowitz Social Anxiety Scale (LSAS) Total Score
  9:
    - object: Area Under the Plasma Concentration-time Curve 
  10:
    - object: Transitional Dyspnea Index (TDI) Score
  11:
    - object: Progression-free Survival
  12:
    - object: Equivalence of Seroprotection Against Poliovirus
  13:
    - measure: Change From Baseline
    - object: Vital Sign Parameter of Heart Rate
  14:
    - object: Brief Psychiatric Rating Scale
  15:
    - measure: Change
  16:
    - object: Lipids
  17:
    - measure: Number
    - object: Invasive Ventilator-Free Survival
  18:
    - object: Inflammatory Bowel Disease Questionnaire (IBDQ) Social Function Domain Score
  19:
    - measure: Number
    - object: Transplants in Which Participants Achieved Platelet (PLT) Engraftment
  20:
    - measure: Change From Baseline
    - object: Subjective Sleep Onset Latency
  21:
    - object: Operator Satisfaction
  22:
    - object: Trough FEV1 Response
  23:
    - measure: Change From Baseline
    - object: Blood Eosinophils (Cells/uL)
  24:
    - measure: Number of Participants
    - object: Most Frequent Grade 3-4 Hematology Abnormalities
  25:
    - object: Maximum Observed Plasma Concentration (Cmax)
  26:
    - measure: Change
    - object: Diabetes
  27:
    - object: Serum Iron
  28:
    - measure: Change From Baseline
    - object: Glucose-Lowering Treatments
  29:
    - measure: Occurrence
    - measure: Severity
    - object: Treatment-emergent Adverse Events (TEAEs)
  30:
    - object: Best Overall Response Rate
  31:
    - measure: Change
    - object: Pediatric Evaluation of Disability Inventory (PEDI) Functional Skills Scores
  32:
    - measure: Percentage of Participants
    - object: Clinical Global Impression Improvement Score
  33:
    - object: Descend Steps Pre-Intervention
  34:
    - measure: Number of Participants
    - object: Each Stage at Maximum Severity
  35:
    - measure: Proportion of the Subjects
    - object: At Least 10mm Difference in VAS Pain Scale Scores
  36:
    - measure: Change
    - object: Adinopectin
  37:
    - measure: Change From Baseline
    - object: HAQ-DI
  38:
    - measure: Number
    - object: Adverse Events
  39:
    - measure: Percentage of Participants
    - object: 20% Improvement (ACR20)
  40:
    - measure: Number of Participants
    - object: TEAEs
    - object: Grade >= 3 TEAEs
    - object: Serious TEAEs
    - object: Treatment Related TEAEs
  41:
    - measure: Number of Patients
    - object: Buccal Cells Demonstrating a Decline in Cyclin D1
  42:
    - measure: Maximum Total Daily Number
    - object: Self-Reported Spray Doses
  43:
    - measure: Change
    - object: Infant Sleep Quantity
  44:
    - measure: Change From Baseline
    - object: Emotional Well-Being (EWB) Subscale Score
  45:
    - measure: Percentage of Participants
    - object: Adverse Events
  46:
    - measure: Number of Participants
    - object: PIK3CA Mutation at Baseline
  47:
    - measure: Compared
    - object: eSAGE Score Compared to Hopkins Verbal Learning Test (HVLT) Score
  48:
    - object: Visual Analog Pain Scale
  49:
    - object: Clinical Global Impressions of Severity (CGI-S) Total Score
  50:
    - object: Patient Satisfaction
  51:
    - object: Corneal Staining Score
  52:
    - measure: Percentage of Subjects
    - object: ≥4-fold Rise for Anti-H2 Full Length HA ELISA Antibody Concentration
  53:
    - measure: Change
    - object: Elvitegravir (EVG) Concentration in Penile Secretions
  54:
    - measure: Change
    - object: PTSD Symptoms
  55:
    - measure: Number of Cases
    - object: Non-Serotype Specific Dengue Viremia
  56:
    - measure: Number of Participants
    - object: High Grade (Grade 3-4) Immune Mediated Adverse Events (IMAEs)
  57:
    - measure: Correlation
    - object: Change in Pain Intensity
    - object: TBW
  58:
    - object: Area Under the Plasma Concentration versus Time Curve (AUC)
  59:
    - measure: Change From Baseline
    - object: MSIS-29 Psychological Score
  60:
    - measure: Time
    - object: Implant Insertion
  61:
    - measure: Percentage of Participants
    - object: Confirmed Best Objective Response
  62:
    - measure: Percentage of Participants
    - object: Treatment-emergent Resistance-associated Substitutions to OBT Components
  63:
    - measure: Change From Baseline
    - object: Exercise Tolerance
  64:
    - measure: Associations
    - object: Polymorphisms
    - object: Efficacy
    - object: Toxicities
  65:
    - measure: Patients Treated
    - object: Response Rate
  66:
    - object: Area Under Curve
  67:
    - measure: Percentage
    - object: Heartburn-Free 24-hour Days
  68:
    - measure: Change From Baseline
    - object: Triiodothyronine (T3) Chemistry Laboratory Test Results
  69:
    - measure: Number of Participants
    - object: Worst Case Body Temperature Values of PCI
  70:
    - measure: Percentage of Patients
    - object: Systolic Blood Pressure <90 mmHg
  71:
    - measure: Number of Participants
    - object: Abnormal Glycosylated Hemoglobin (HbA1c) Value
  72:
    - object: Concentration in Serum
  73:
    - measure: Occurrence Rate
    - object: Surgical Site
  74:
    - measure: Rate of Decline
    - object: Forced Vital Capacity (FVC)
  75:
    - object: Maternal Morbidity
  76:
    - object: CD22 Expression Levels
  77:
    - measure: Change
    - object: Basophils
  78:
    - measure: Number of Participants
    - object: Rescue Medication
  79:
    - measure: Number of Participants
    - object: Pathogen Identified by the Karius Test
  80:
    - measure: Time to Need
    - object: Inhaled and/or IV Antipseudomonal Antibiotics
  81:
    - measure: Incidence
    - object: Cervical Intraepithelial Neoplasia
  82:
    - measure: Change From Baseline
    - object: SBP
  83:
    - object: Safety
  84:
    - measure: Percent Change From Baseline
    - object: Low Density Lipoprotein Cholesterol (LDL-C)
  85:
    - object: Hot Flash Related Daily Interference Scale (HFRDIS)
  86:
    - measure: Change From Baseline
    - object: Mean Worse Eye Intraocular Pressure (IOP)
  87:
    - measure: Change From Baseline
    - object: Cartilage Thickness of the Total Tibiofemoral Compartment (tTFC)
  88:
    - measure: Change From Baseline
    - object: Brief Fatigue Inventory (BFI) Worst Fatigue Score
  89:
    - object: AUC
  90:
    - measure: Percentage of Participants
    - object: Recurrent Disease
  91:
    - object: Progression-free Survival
  92:
    - measure: Changes
    - object: Health Assessment Questionnaire-Disability Index (HAQ-DI©)
  93:
    - object: Snack Added Sugars Purchased
  94:
    - measure: Number of Participants
    - object: Overall Survival
  95:
    - measure: Change From Baseline
    - object: Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain Sub-scores
    - object: Knee Injury and Osteoarthritis Outcome Score (KOOS) ADL Sub-scores
  96:
    - measure: Magnitude of Suppression
    - object: Plasma Renin Activity
  97:
    - object: Terminal Half-life (T½)
  98:
    - measure: Number
    - object: Eyelids With Each of the Trichiasis Severity Levels
  99:
    - measure: Effect
    - object: Retrospective-Modified Overt Aggression Scale (R-MOAS) Remission Rate
  100:
    - measure: Number of Patients
    - object: Adverse Effects
  101:
    - measure: Mean
    - object: Pre-dose Peak Expiratory Flow (PEF)
  102:
    - measure: Percentage of Participants
    - object: Disease Control in Participants With Low ERCC-1 Levels
  103:
    - measure: Change
    - object: BCVA in Non-treated Contralateral Eye
  104:
    - measure: Change From Baseline
    - object: Forced Expiratory Volume in One Second (FEV1)
  105:
    - object: Asthma Symptom Score (Night-time)
  106:
    - measure: Pharmacokinetic Parameters
    - object: tmax
  107:
    - object: Maximum Observed Concentration
